The latest price target for Axsome Therapeutics (NASDAQ:AXSM) was reported by Morgan Stanley on May 5, 2026. The analyst firm set a price target for $242.00 expecting AXSM to rise to within 12 months (a possible 4.34% upside). 49 analyst firms have reported ratings in the last year.

The latest analyst rating for Axsome Therapeutics (NASDAQ:AXSM) was provided by Morgan Stanley, and Axsome Therapeutics maintained their equal-weight rating.

There is no last upgrade for Axsome Therapeutics

The last downgrade for Axsome Therapeutics Inc happened on January 8, 2026 when Morgan Stanley changed their price target from $196 to $204 for Axsome Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Axsome Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Axsome Therapeutics was filed on May 5, 2026 so you should expect the next rating to be made available sometime around May 5, 2027.

While ratings are subjective and will change, the latest Axsome Therapeutics (AXSM) rating was a maintained with a price target of $217.00 to $242.00. The current price Axsome Therapeutics (AXSM) is trading at is $231.93, which is within the analyst’s predicted range.